Samchundang Pharm Submits European Clinical Trial Application for Oral Insulin
Samchundang Pharm announced on the 19th that it has submitted a Clinical Trial Application (CTA) to the European Medicines Agency (EMEA) for its oral insulin candidate.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The purpose of the clinical trial is to evaluate and compare the pharmacokinetic and pharmacodynamic properties of the oral insulin candidate (SCD0503) with those of subcutaneous insulin under normal glucose clamp conditions in patients with type 1 diabetes. The clinical trial period is expected to be within approximately nine months from the date of approval.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.